[Infostock Daily= Reporter An Hoe Hyun] SK Securities said on the 10th that sales of vaccine CMO will expand in earnest from next year for SK Chemicals, and that there is a high possibility of additional orders due to plant expansion.
"AstraZeneca, a major vaccine CMO customer of SK Chemicals, will announce the results of the Phase III clinical trials of the COVID-19 vaccine this year and submit it to regulators to apply for approval for emergency use in as many countries as possible in its third quarter earnings report," the company said, adding, "COVID-19 vaccination will be available as early as January next year."
"When the vaccination of the COVID-19 vaccine begins in earnest, SK Chemical's vaccine CMO will also begin production early next year and will be positive for improving its performance," the company explained, adding, "As the vaccine CMO business is being highlighted due to the global lack of production capacity, it will be able to win additional orders after the establishment of plans to expand the plant next year."
Also, the company analyzed, "MSCI index inflow is expected to serve as a positive momentum for SK Chemical's stock price, which is expected to lead to a long-term upward trend in stock prices."
Reporter An Hoe Hyun ahh@infostock.co.kr
